Introduction:
Rentschler Biopharma SE, a contract development and manufacturing organization (CDMO), has expanded its production capacity at its site in Milford, USA. This expansion doubles Rentschler’s cGMP-compliant production capacity and allows the company to produce highly complex biologics in the USA. The new production line took three years to build and includes additional cleanroom space and bioreactors. The expansion is the largest investment in Rentschler Biopharma’s 150-year history.
- Rentschler Biopharma has launched a new production line at its site in Milford, USA, doubling its cGMP-compliant production capacity.
- The expansion allows the company to produce highly complex biologics in the USA.
- The new production line took three years to build and includes additional cleanroom space and bioreactors.
- CEO Benedikt von Braunmühl intends to use the increased production capacity to expand in the area of highly complex biologics in the USA.
- According to Tom Roberts, President of Rentschler Biopharma Inc., the new production line will help the company attract new clients and expand partnerships with existing clients.
Conclusion:
Rentschler Biopharma has expanded its production capacity in the USA, allowing the company to produce highly complex biologics. This expansion is a significant investment for the company and will help attract new clients and expand partnerships with existing clients. The expanded production line will support the growth of Rentschler Biopharma and its commitment to providing high-quality biopharmaceuticals.
